New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 3, 2014
17:52 EDTCAPR, JNJCapricor gets $12.5M upfront payment in Janssen development agreement
Capricor Therapeutics (CAPR) disclosed in a regulatory filing that it entered into a collaboration agreement and with Janssen Biotech, a wholly-owned subsidiary of Johnson & Johnson (JNJ). Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricorís cell therapy program for cardiovascular applications, including its lead product, CAP-1002. Capricor and Janssen further agreed to collaborate on the development of cell manufacturing in preparation for future clinical trials. Under the agreement, Capricor will receive an upfront cash payment of $12.5M from Janssen, and Capricor will also contribute to the costs of development of a chemistry, manufacturing and controls package. In addition, Janssen will have the exclusive right to enter into an exclusive license agreement pursuant to which Janssen would receive a worldwide, exclusive license to exploit CAP-1002 as well as certain allogeneic cardiospheres and cardiosphere-derived cells in the field of cardiology. Janssen has the right to exercise the option at any time until sixty days after the delivery by Capricor of the six-month follow-up results from Phase II of Capricorís ALLSTAR clinical trial for CAP-1002. If Janssen exercises its option rights, Capricor would receive an upfront license fee and additional milestone payments which may total up to $325M. In addition, a double-digit royalty would be paid on commercial sales of licensed products
News For CAPR;JNJ From The Last 14 Days
Check below for free stories on CAPR;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 30, 2014
08:31 EDTJNJJohnson & Johnson agrees to acquire Alios BioPharma for $1.75B
Subscribe for More Information
08:16 EDTJNJTetraphase price target raised to $32 from $20 at JMP Securities
Subscribe for More Information
07:30 EDTJNJSachs Associates to hold a conference
14th Annual Biotech in Europe Forum for Global Partnering and Investment to be held in Basel, Switzerland on September 30-October 1.
September 24, 2014
17:59 EDTJNJOdds of Colgate-Palmolive takeover rise amid slew of megamergers, Bloomberg says
Subscribe for More Information
September 23, 2014
08:07 EDTJNJFDA Pediatric Advisory Committee to hold a meeting
Subscribe for More Information
September 22, 2014
07:50 EDTJNJDoctors continue to use morcellators despite FDA warning, J&J halt, WSJ says
Subscribe for More Information
07:07 EDTJNJSynageva appoints Robert Bazemore as COO
Synageva announced the appointment of Robert Bazemore as Chief Operating Officer. Bazemore will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations. Bazemore last served at Johnson & Johnson (JNJ) in varoius roles including Vice President, Ethicon New Growth Platforms and President of Janssen Biotech, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
September 18, 2014
08:10 EDTCAPRCapricor presents ALLSTAR Phase I preliminary results
Subscribe for More Information
September 17, 2014
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information
September 16, 2014
07:31 EDTJNJEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use